Showing results (2021-2030 of 3,160) with videos related to

Sort By:
Pageof 316
Neuro-Oncology|December 17, 2008
Regulatory effect of nerve growth factor in alpha9beta1 integrin-dependent progression of glioblastomaMeghan C Brown, Izabela Staniszewska, Philip Lazarovici, et al.
Neuro-Oncology|February 20, 2009
Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951Mathilde C M Kouwenhoven, Thierry Gorlia, Johan M Kros, et al.
Neuro-Oncology|February 3, 2009
Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumorsHelge R Brekke, Matthias Kolberg, Rolf I Skotheim, et al.
Neuro-Oncology|November 27, 2008
Age-incidence patterns of primary CNS tumors in children, adolescents, and adults in EnglandRamandeep S Arora, Robert D Alston, Tim O B Eden, et al.
Neuro-Oncology|November 27, 2008
Lactate promotes glioma migration by TGF-beta2-dependent regulation of matrix metalloproteinase-2Fusun Baumann, Petra Leukel, Anett Doerfelt, et al.
Neuro-Oncology|December 4, 2008
Pediatric giant cell glioblastoma: New insights into a rare tumor entityMichael Karremann, Sandra Butenhoff, Ulrike Rausche, et al.
Neuro-Oncology|August 30, 2008
Postradiation lumbosacral radiculopathy with spinal root cavernomas mimicking carcinomatous meningitisFrançois Ducray, Rémy Guillevin, Dimitri Psimaras, et al.
Neuro-Oncology|September 2, 2008
Colon perforation during antiangiogenic therapy for malignant gliomaAndrew D Norden, Jan Drappatz, Abigail Slate Ciampa, et al.
Neuro-Oncology|September 6, 2008
New (alternative) temozolomide regimens for the treatment of gliomaWolfgang Wick, Michael Platten, Michael Weller
Neuro-Oncology|November 17, 2006
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiformeKarla V Ballman, Jan C Buckner, Paul D Brown, et al.
Pageof 316